What United Therapeutics (UTHR)'s Goldman Sell Call Amid Bold Pipeline And Buyback Means For Shareholders
Source: Simply Wall St. ·
Earlier this week, Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, even as the company pursues an ambitious pipeline of 14 potential launches, including nebulized Tyvaso for idiopathic pulmonary fibrosis and once-daily oral ralinepag, alongside a US$2.00 billion share repurchase authorization. At the same time, United Therapeutics is pushing ahead with long-horizon…